EM2005C "Disease Modifying and Biologic Agent Use in COVID-19 Infection - A Rheumatologic Perspective" (IM GR-050120)

Purpose: to discuss the rationale for using existing Rheumatologic agents - disease modifying antirheumatic drugs (DMARDs) and biologic agents, in the treatment of those infected with the Coronavirus, and to discuss the safety, efficacy, potential toxicities and clinical trials for this drugs and where they may be used during the COVID-19 crisis.

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Be aware of the potential mechanistic benefits of antimalarial or JAK inhibitor therapy in COVID-19 infection
  • Understand the similarities and treatment for the Cytokine Storm Syndrome and Macrophage Activation Syndrome
  • Be aware of the potential use of corticosteroids, colchicine and other biologic in seriously infected COVID-19 patients
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
Course expires: 

Photo: John J. Cush, M.D.John J. Cush, M.D.
Professor of Internal Medicine
Division of Rheumatic Diseases

Available Credit

  • 1.00 AMA


Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome